{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:11:00Z","timestamp":1778253060632,"version":"3.51.4"},"reference-count":76,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009457","name":"Region Sj\u00e6lland","doi-asserted-by":"publisher","award":["R17-A36-B30"],"award-info":[{"award-number":["R17-A36-B30"]}],"id":[{"id":"10.13039\/501100009457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background and Purpose: Calcium electroporation (CaEP) involves injecting calcium into tumour tissues and using electrical pulses to create membrane pores that induce cell death. This study assesses resultant immune responses and histopathological changes in patients with cutaneous metastases.\nPatients\/Materials and Methods: The aimed cohort comprised 24 patients with metastases exceeding 5 mm. Tumours were treated once with CaEP (day 0) or twice (day 28). Biopsies were performed on days 0 and 2, with additional samples on days 7, 28, 30, 35, 60, and 90 if multiple tumours were treated. The primary endpoint was the change in tumour-infiltrating lymphocytes (TILs) two days post-treatment, with secondary endpoints evaluating local and systemic immune responses via histopathological analysis of immune markers, necrosis, and inflammation.\nResults: Seventeen patients, with metastases primarily from breast cancer (14 patients), but also lung cancer (1), melanoma (1), and urothelial cancer (1), completed the study. Of the 49 lesions treated, no significant changes in TIL count or PD-L1 expression were observed. However, there was substantial necrosis and a decrease in FOXP3-expression (p = 0.0025) noted, with a slight increase in CD4+ cells but no changes in CD3, CD8, or CD20 expressions. Notably, four patients showed reduced tumour invasiveness, including one case of an abscopal response.\nInterpretation: This exploratory study indicates that CaEP can be an effective anti-tumour therapy potentially enhancing immunity. Significant necrosis and decreased regulatory lymphocytes were observed, although TIL count remained unchanged. Several patients exhibited clinical signs of immune response following treatment.<\/jats:p>","DOI":"10.2340\/1651-226x.2024.19462","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T09:45:01Z","timestamp":1716889501000},"page":"398-410","source":"Crossref","is-referenced-by-count":2,"title":["Immune cell populations in the tumour environment following calcium electropora\u00adtion for cutaneous metastasis: a histopathological study"],"prefix":"10.2340","volume":"63","author":[{"given":"Mille","family":"Vissing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sinius Pouplier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Munch Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stine","family":"Krog Frandsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Lodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Vibeke","family":"L\u00e6nkholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Gehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"62618","doi-asserted-by":"crossref","unstructured":"Frandsen SK, Gissel H, Hojman P, et al. Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Res. 2012;72(6):1336\u201341.","DOI":"10.1158\/0008-5472.CAN-11-3782"},{"key":"62619","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3782","DOI":"10.1158\/0008-5472.CAN-11-3782"},{"key":"62620","doi-asserted-by":"crossref","unstructured":"Hoejholt KL, Mu\u017ei\u0107 T, Jensen SD, et al. Calcium electroporation and electrochemotherapy for cancer treatment: importance of cell membrane composition investigated by lipidomics, calorimetry and in vitro efficacy. Sci Rep. 2019;9(1):4758.","DOI":"10.1038\/s41598-019-41188-z"},{"key":"62621","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41598-019-41188-z","DOI":"10.1038\/s41598-019-41188-z"},{"key":"62622","doi-asserted-by":"crossref","unstructured":"Frandsen SK, Vissing M, Gehl J. A comprehensive review of calcium electroporation \u2013 a novel cancer treatment modality. Cancers. 2020;12(2):290.","DOI":"10.3390\/cancers12020290"},{"key":"62623","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers12020290","DOI":"10.3390\/cancers12020290"},{"key":"62624","doi-asserted-by":"crossref","unstructured":"Staresinic B, Jesenko T, Kamensek U, et al. Effect of calcium electroporation on tumour vasculature. Sci Rep. 2018;8(1):9412.","DOI":"10.1038\/s41598-018-27728-z"},{"key":"62625","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/s41598-018-27728-z","DOI":"10.1038\/s41598-018-27728-z"},{"key":"62626","doi-asserted-by":"crossref","unstructured":"Hansen EL, Sozer EB, Romeo S, et al. Dose-dependent ATP depletion and cancer cell death following calcium electroporation, relative effect of calcium concentration and electric field strength. PLoS One. 2015;10(4):e0122973.","DOI":"10.1371\/journal.pone.0122973"},{"key":"62627","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0122973","DOI":"10.1371\/journal.pone.0122973"},{"key":"62628","doi-asserted-by":"crossref","unstructured":"Falk H, Forde PF, Bay ML, et al. Calcium electroporation induces tumor eradication, long-lasting immunity and cytokine responses in the CT26 colon cancer mouse model. Oncoimmunology. 2017;6(5):e1301332.","DOI":"10.1080\/2162402X.2017.1301332"},{"key":"62629","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/2162402X.2017.1301332","DOI":"10.1080\/2162402X.2017.1301332"},{"key":"62630","doi-asserted-by":"crossref","unstructured":"Frandsen SK, Kr\u00fcger MB, Mangalanathan UM, et al. Normal and malignant cells exhibit differential responses to calcium electroporation. Cancer Res. 2017;77(16):4389\u2013401.","DOI":"10.1158\/0008-5472.CAN-16-1611"},{"key":"62631","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1611","DOI":"10.1158\/0008-5472.CAN-16-1611"},{"key":"62632","doi-asserted-by":"crossref","unstructured":"Ghosh S, Yang R, Duraki D, et al. Plasma membrane channel TRPM4 mediates immunogenic therapy-induced necrosis. Cancer Res. 2023;83(18):3115\u201330.","DOI":"10.1158\/0008-5472.CAN-23-0157"},{"key":"62633","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0157","DOI":"10.1158\/0008-5472.CAN-23-0157"},{"key":"62634","doi-asserted-by":"crossref","unstructured":"Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Ann Rev Immunol. 2013;31:51\u201372.","DOI":"10.1146\/annurev-immunol-032712-100008"},{"key":"62635","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1146\/annurev-immunol-032712-100008","DOI":"10.1146\/annurev-immunol-032712-100008"},{"key":"62636","doi-asserted-by":"crossref","unstructured":"Lisec B, Markelc B, Ursic Valentinuzzi K, et al. The effectiveness of calcium electroporation combined with gene electrotransfer of a plasmid encoding IL-12 is tumor type-dependent. Front Immunol. 2023;14:1189960.","DOI":"10.3389\/fimmu.2023.1189960"},{"key":"62637","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2023.1189960","DOI":"10.3389\/fimmu.2023.1189960"},{"key":"62638","doi-asserted-by":"crossref","unstructured":"Badoual C, Hans S, Merillon N, et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013;73(1):128\u201338.","DOI":"10.1158\/0008-5472.CAN-12-2606"},{"key":"62639","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2606","DOI":"10.1158\/0008-5472.CAN-12-2606"},{"key":"62640","doi-asserted-by":"crossref","unstructured":"Falk H, Lambaa S, Johannesen HH, et al. Electrochemotherapy and calcium electroporation inducing a systemic immune response with local and distant remission of tumors in a patient with malignant melanoma \u2013 a case report. Acta Oncol. 2017;56(8):1126\u201331.","DOI":"10.1080\/0284186X.2017.1290274"},{"key":"62641","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2017.1290274","DOI":"10.1080\/0284186X.2017.1290274"},{"key":"62642","doi-asserted-by":"crossref","unstructured":"Falk H, Matthiessen LW, Wooler G, et al. Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy. Acta Oncol. 2018;57(3):311\u201319.","DOI":"10.1080\/0284186X.2017.1355109"},{"key":"62643","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2017.1355109","DOI":"10.1080\/0284186X.2017.1355109"},{"key":"62644","doi-asserted-by":"crossref","unstructured":"Plaschke CC, Gehl J, Johannesen HH, et al. Calcium electroporation for recurrent head and neck cancer: a clinical phase I study. Laryngoscope Investig Otolaryngol. 2019;4(1):49\u201356.","DOI":"10.1002\/lio2.233"},{"key":"62645","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/lio2.233","DOI":"10.1002\/lio2.233"},{"key":"62646","doi-asserted-by":"crossref","unstructured":"\u00c1goston D, Balt\u00e1s E, \u00d3csai H, et al. Evaluation of calcium electroporation for the treatment of cutaneous metastases: a double blinded randomised controlled phase II trial. Cancers. 2020;12(1):179.","DOI":"10.3390\/cancers12010179"},{"key":"62647","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers12010179","DOI":"10.3390\/cancers12010179"},{"key":"62648","doi-asserted-by":"crossref","unstructured":"Jensen KB, Lonkvist CK, Gehl J, et al. Calcium electroporation for management of cutaneous metastases in HER2-positive breast cancer: A case report. Case Rep Dermatol 2022;14(3):330\u20138.","DOI":"10.1159\/000526157"},{"key":"62649","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000526157","DOI":"10.1159\/000526157"},{"key":"62650","doi-asserted-by":"crossref","unstructured":"Teng MW, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139\u201345.","DOI":"10.1158\/0008-5472.CAN-15-0255"},{"key":"62651","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0255","DOI":"10.1158\/0008-5472.CAN-15-0255"},{"key":"62652","doi-asserted-by":"crossref","unstructured":"Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321.","DOI":"10.1056\/NEJMoa1809615"},{"key":"62653","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1809615","DOI":"10.1056\/NEJMoa1809615"},{"key":"62654","doi-asserted-by":"crossref","unstructured":"Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","DOI":"10.1038\/nature14011"},{"key":"62655","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/nature14011","DOI":"10.1038\/nature14011"},{"key":"62656","doi-asserted-by":"crossref","unstructured":"Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374.","DOI":"10.1158\/1078-0432.CCR-13-3271"},{"key":"62657","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271","DOI":"10.1158\/1078-0432.CCR-13-3271"},{"key":"62658","doi-asserted-by":"crossref","unstructured":"Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259\u201371.","DOI":"10.1093\/annonc\/mdu450"},{"key":"62659","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdu450","DOI":"10.1093\/annonc\/mdu450"},{"key":"62660","doi-asserted-by":"crossref","unstructured":"Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559\u201369.","DOI":"10.1200\/JCO.18.01010"},{"key":"62661","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.18.01010","DOI":"10.1200\/JCO.18.01010"},{"key":"62662","doi-asserted-by":"crossref","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","DOI":"10.1016\/S1470-2045(17)30904-X"},{"key":"62663","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(17)30904-X","DOI":"10.1016\/S1470-2045(17)30904-X"},{"key":"62664","doi-asserted-by":"crossref","unstructured":"Vissing M, Ploen J, Pervan M, et al. Study protocol designed to investigate tumour response to calcium electroporation in cancers affecting the skin: a non-randomised phase II clinical trial. BMJ Open. 2021;11(6):e046779.","DOI":"10.1136\/bmjopen-2020-046779"},{"key":"62665","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1136\/bmjopen-2020-046779","DOI":"10.1136\/bmjopen-2020-046779"},{"key":"62666","doi-asserted-by":"crossref","unstructured":"Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020;38(12):1346\u20136.","DOI":"10.1200\/JCO.19.02309"},{"key":"62667","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1200\/JCO.19.02309","DOI":"10.1200\/JCO.19.02309"},{"key":"62668","doi-asserted-by":"crossref","unstructured":"Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241\u201356.","DOI":"10.5858\/arpa.2013-0953-SA"},{"key":"62669","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.5858\/arpa.2013-0953-SA","DOI":"10.5858\/arpa.2013-0953-SA"},{"key":"62670","doi-asserted-by":"crossref","unstructured":"Gundersen HJG. Notes on the estimation of the numerical density of arbitrary profiles: the edge effect. J Microsc. 1977;111(2):219\u201323.","DOI":"10.1111\/j.1365-2818.1977.tb00062.x"},{"key":"62671","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2818.1977.tb00062.x","DOI":"10.1111\/j.1365-2818.1977.tb00062.x"},{"key":"62672","doi-asserted-by":"crossref","unstructured":"Vissing M, Munch Larsen L, Christensen AJ, et al. Calcium electroporation as an adjunct therpay for pembrolizumab-resistant bladder cancer: a case report. Acta Oncol. 2023;62(6):614\u201320.","DOI":"10.1080\/0284186X.2023.2226330"},{"key":"62673","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/0284186X.2023.2226330","DOI":"10.1080\/0284186X.2023.2226330"},{"key":"62674","doi-asserted-by":"crossref","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, et al. Natural innate and adaptive immunity to cancer. Ann Rev Immunol. 2011;29:235\u201371.","DOI":"10.1146\/annurev-immunol-031210-101324"},{"key":"62675","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1146\/annurev-immunol-031210-101324","DOI":"10.1146\/annurev-immunol-031210-101324"},{"key":"62676","doi-asserted-by":"crossref","unstructured":"Gajewski TF, Woo SR, Zha Y, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25(2):268\u201376.","DOI":"10.1016\/j.coi.2013.02.009"},{"key":"62677","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.coi.2013.02.009","DOI":"10.1016\/j.coi.2013.02.009"},{"key":"62678","doi-asserted-by":"crossref","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330\u20136.","DOI":"10.1038\/ni904"},{"key":"62679","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/ni904","DOI":"10.1038\/ni904"},{"key":"62680","doi-asserted-by":"crossref","unstructured":"Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009;30(5):636\u201345.","DOI":"10.1016\/j.immuni.2009.04.010"},{"key":"62681","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.immuni.2009.04.010","DOI":"10.1016\/j.immuni.2009.04.010"},{"key":"62682","doi-asserted-by":"crossref","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27(1):109\u201318.","DOI":"10.1038\/cr.2016.151"},{"key":"62683","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/cr.2016.151","DOI":"10.1038\/cr.2016.151"},{"key":"62684","doi-asserted-by":"crossref","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690\u2013714.","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"62685","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012","DOI":"10.1016\/j.ccell.2015.10.012"},{"key":"62686","doi-asserted-by":"crossref","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865\u201374.","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"key":"62687","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1507","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"key":"62688","doi-asserted-by":"crossref","unstructured":"Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","DOI":"10.1186\/s13045-022-01242-2"},{"key":"62689","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s13045-022-01242-2","DOI":"10.1186\/s13045-022-01242-2"},{"key":"62690","doi-asserted-by":"crossref","unstructured":"Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol. 2012;2:95.","DOI":"10.3389\/fonc.2012.00095"},{"key":"62691","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2012.00095","DOI":"10.3389\/fonc.2012.00095"},{"key":"62692","doi-asserted-by":"crossref","unstructured":"Vissing M, Pervan M, Pl\u00f8en J, et al. Calcium electroporation in cutaneous metastases \u2013 a non-randomised phase II multicentre clinical trial. Eur J Surgical Oncol. 2023;49(9):106925.","DOI":"10.1016\/j.ejso.2023.04.024"},{"key":"62693","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejso.2023.04.024","DOI":"10.1016\/j.ejso.2023.04.024"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/19462\/46291","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/19462\/46291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:03:41Z","timestamp":1756404221000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/19462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":76,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2024.19462","relation":{},"ISSN":["1651-226X","0284-186X"],"issn-type":[{"value":"1651-226X","type":"electronic"},{"value":"0284-186X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}